NANO — Nanobiotix SA Income Statement
0.000.00%
- €135.58m
- €134.80m
- -€11.61m
Annual income statement for Nanobiotix SA, fiscal year end - December 31st, EUR millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | ARS | ARS | ARS | ARS | ARS |
Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 0.05 | 0.01 | 0 | 30.1 | -11.6 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Depreciation and Amortization | |||||
Unusual Expense / Income | |||||
Other Operating Expenses | |||||
Total Operating Expenses | 36.5 | 52.6 | 53.6 | 56.6 | 54 |
Operating Profit | -36.4 | -52.6 | -53.6 | -26.5 | -65.6 |
Total Net Non Operating Interest Income / Expense | |||||
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | -33.6 | -47 | -57 | -39.6 | -68 |
Provision for Income Taxes | |||||
Net Income After Taxes | -33.6 | -47 | -57 | -39.7 | -68.1 |
Net Income Before Extraordinary Items | |||||
Net Income | -33.6 | -47 | -57 | -39.7 | -68.1 |
Adjustments to Net Income | |||||
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | -33.6 | -47 | -57 | -39.7 | -68.1 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | -1.38 | -1.35 | -1.51 | -1.08 | -1.48 |
Dividends per Share |